AGMB.NB
AGMB10.850USD
-1.020-8.59%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
528.79MMarket Cap
LossP/E TTM
More Details of AGMB.NB Company
Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.
AGMB.NB Info
Ticker SymbolAGMB
Company nameAgomab Therapeutics NV
IPO dateFeb 06, 2026
CEOKnotnerus (Tim)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endFeb 06
AddressPosthoflei 1/6
City
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryBelgium
Postal code2600
Phone
Websitehttps://agomab.com/
Ticker SymbolAGMB
IPO dateFeb 06, 2026
CEOKnotnerus (Tim)
Company Executives of AGMB.NB
Name
Name/Position
Position
Shareholding
Change
Mr. Tim Knotnerus
Mr. Tim Knotnerus
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
10.82K
--
,
,
--
--
Mrs. Ellen Lefever
Mrs. Ellen Lefever
General Counsel
General Counsel
--
--
Dr. Paul van der Horst
Dr. Paul van der Horst
Chief Business Officer
Chief Business Officer
--
--
Dr. Philippe Wiesel
Dr. Philippe Wiesel
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrea Saez
Dr. Andrea Saez
Chief Development Officer
Chief Development Officer
--
--
Mr. Pierre Kemula
Mr. Pierre Kemula
Chief Financial Officer
Chief Financial Officer
--
--
Mr. David R. Epstein
Mr. David R. Epstein
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Angelika Jahreis
Ms. Angelika Jahreis
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Colin Bond
Mr. Colin Bond
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Tim Knotnerus
Mr. Tim Knotnerus
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
10.82K
--
,
,
--
--
Mrs. Ellen Lefever
Mrs. Ellen Lefever
General Counsel
General Counsel
--
--
Dr. Paul van der Horst
Dr. Paul van der Horst
Chief Business Officer
Chief Business Officer
--
--
Dr. Philippe Wiesel
Dr. Philippe Wiesel
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrea Saez
Dr. Andrea Saez
Chief Development Officer
Chief Development Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Mar 17
Updated: Tue, Mar 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
9.90%
EQT Life Sciences
2.29%
Knotnerus (Tim)
0.02%
Other
87.79%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
9.90%
EQT Life Sciences
2.29%
Knotnerus (Tim)
0.02%
Other
87.79%
Shareholder Types
Shareholders
Proportion
Investment Advisor
9.90%
Venture Capital
2.29%
Individual Investor
0.02%
Other
87.79%
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Reporting Period
No. of institutions
Shares Held
Proportion
Change
No Data
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
No Data
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
